{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:40:39Z","timestamp":1773286839938,"version":"3.50.1"},"reference-count":107,"publisher":"Informa Healthcare","issue":"5","funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.1185\/03007995.2016.1151774","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T22:13:08Z","timestamp":1454969588000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Sodium\u2013glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes"],"prefix":"10.1185","volume":"32","author":[{"given":"Stanley S.","family":"Schwartz","sequence":"first","affiliation":[{"name":"Main Line Health System, Ardmore, PA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Intekhab","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"CIT0001","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014. 2014. Available at: http:\/\/www.cdc.gov\/diabetes\/pubs\/statsreport14\/national-diabetes-report-web.pdf [Last accessed 23 September 2015]"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.732"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10029"},{"key":"CIT0004","author":"Ligthart S","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"CIT0005","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014: data sources, methods, and references for estimates of diabetes and its burden in the United States. 2014. Available at: http:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/2014-report-national-diabetes-statistics-report-data-sources.pdf [Last accessed 24 July 2015]"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-S018"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3201"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0669"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0436-2"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.9.5.665"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010815"},{"key":"CIT0012","first-page":"1","volume":"13","author":"UK Prospective Diabetes Study 6.","year":"1990","journal-title":"Diabetes Res"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.03.001"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62154-6"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1585"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2012.07.2569"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"CIT0019","volume-title":"Full Prescribing Information","author":"Jardiance (empagliflozin).","year":"2014"},{"key":"CIT0020","volume-title":"Full Prescribing Information","author":"Farxiga (dapagliflozin).","year":"2015"},{"key":"CIT0021","volume-title":"Dapagliflozin improves glycaemic control and reduces body weight as add-on therapy to metformin plus sulphonylurea","author":"Matthaei S","year":"2013"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02681.x"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.71"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2008.01043.x"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1800.2011.00551.x"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S301"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0095-4543(05)70130-5"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01511.x"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.4158\/EP.14.6.782"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0387"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000084"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.02.010"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814544153"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.935764"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1237"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"CIT0049","volume-title":"Canagliflozin demonstrates durable glycaemic improvements over 104 weeks compared with glimepiride in subjects with type 2 diabetes mellitus on metformin","author":"Langslet G","year":"2013"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.11.002"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12325"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-43"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12459"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1142"},{"key":"CIT0065","first-page":"208","volume":"1","author":"Roden M","year":"2013","journal-title":"Lancet"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70120-2"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2105"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2364"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2365"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12187"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0169-9"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.4158\/EP15693.CS"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12189"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1596"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0666"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0699"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.01.2720"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.04.012"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.05.004"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.890925"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2014.38.4.261"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0473"},{"key":"CIT0087","unstructured":"US Food and Drug Administration. SGLT2 Inhibitors: Drug Safety Communication \u2013 Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections. 2015. Available at: http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm475553.htm [Last accessed 6 January 2016]"},{"key":"CIT0088","unstructured":"FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm [Last accessed 6 January 2016]"},{"key":"CIT0089","unstructured":"European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/Procedure_started\/WC500187926.pdf [Last accessed 29 September 2015]"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380"},{"key":"CIT0093","unstructured":"American Association of Clinical Endocrinologists. Leading U.S. Medical Association's Assembly of Domestic and International Diabetes Experts Concludes Use of SGLT2 Inhibitors for Treatment of Diabetes Should Continue With No Changes in Current Recommendations. 2015. Available at: http:\/\/media.aace.com\/press-release\/leading-us-medical-associations-assembly-domestic-and-international-diabetes-experts-c [Last accessed 12 February 2016]"},{"key":"CIT0094","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm461449.htm [Last accessed 29 September 2015]"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3196-x"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3472"},{"key":"CIT0098","volume-title":"Diabetes Case Studies","author":"Schwartz S.","year":"2015","edition":"1"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.052"},{"key":"CIT0100","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S51665"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04010609"},{"key":"CIT0102","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh366"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"CIT0105","unstructured":"Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). 2015. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01730534?term=declare&rank=2 [Last accessed 16 March 2015]"},{"key":"CIT0106","volume-title":"No Increased Risk of Cardiovascular Events with Dapagliflozin in Elderly Patients with Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension [abstract]","author":"Gause-Nilsson I.","year":"2015"},{"key":"CIT0107","unstructured":"Center for Drug Evaluation and Research. Summary Review. Application number 204042Orig1s000. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204042Orig1s000SumR.pdf [Last accessed 21 December 2015]"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2016.1151774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T01:59:19Z","timestamp":1599443959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2016.1151774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.1185\/03007995.2016.1151774"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2016.1151774","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}